Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6706480 | 0.83 | RXFP1 (0.44) | POLA1CYP1A2HPGDCYP2C19EGLN1 | |
| SCHEMBL6279583 | 0.79 | KCNH2 (0.65) | POLA1 | |
| SCHEMBL6631743 | 0.76 | RXFP1 (0.43) | MEN1KMT2ACYP1A2HPGDCYP2C19 | |
| SCHEMBL6287440 | 0.76 | TDP1 (0.51) | POLA1MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL6709038 | 0.76 | KCNH2 (0.69) | — | |
| SCHEMBL6632019 | 0.75 | KCNH2 (0.56) | — | |
| SCHEMBL6706672 | 0.75 | KCNH2 (0.56) | — | |
| SCHEMBL6706383 | 0.74 | KCNH2 (0.55) | — | |
| SCHEMBL6636156 | 0.74 | KCNH2 (0.45) | — | |
| SCHEMBL6280142 | 0.74 | EGLN1 (0.50) | POLA1MEN1KMT2ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176366-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-09-09 | — | — | US | claimed |
| US-20040142928-A1 | Heterocycle carboxamides as antiviral agents | BUNDY GORDON L (US) | 2004-07-22 | — | — | US | claimed |
| WO-2004019933-A1 | METHOD OF PREVENTING OR TREATING ATHEROSCLEROSIS OR RESTENOSIS | PHARMACIA & UPJOHN COMPANY (US) | 2004-03-11 | — | — | WO | claimed |
| US-20030207880-A1 | Heterocycle carboxamides as antiviral agents | BUNDY GORDON L (US) | 2003-11-06 | — | — | US | claimed |
| EP-1301493-A2 | HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-04-16 | — | — | EP | claimed |
| US-20020025960-A1 | Heterocycle carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-02-28 | — | — | US | claimed |
| WO-2002004444-A2 | HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-17 | — | — | WO | claimed |
| US-6903097-B2 | Heterocycle carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY (US) | 2005-06-07 | — | — | US | disclosed |
| US-20040176366-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-09-09 | — | — | US | disclosed |
| US-20040142928-A1 | Heterocycle carboxamides as antiviral agents | BUNDY GORDON L (US) | 2004-07-22 | — | — | US | disclosed |
| WO-2004019933-A1 | METHOD OF PREVENTING OR TREATING ATHEROSCLEROSIS OR RESTENOSIS | PHARMACIA & UPJOHN COMPANY (US) | 2004-03-11 | — | — | WO | disclosed |
| US-20030207880-A1 | Heterocycle carboxamides as antiviral agents | BUNDY GORDON L (US) | 2003-11-06 | — | — | US | disclosed |
| US-6559145-B2 | Herpes virus | PHARMACIA & UPJOHN COMPANY | 2003-05-06 | — | — | US | disclosed |
| EP-1301493-A2 | HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-04-16 | — | — | EP | disclosed |
| US-20020025960-A1 | Heterocycle carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-02-28 | — | — | US | disclosed |
| WO-2002004444-A2 | HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176366-A1 | Method of preventing or treating atherosclerosis or restenosis | LDLR, NR1H3, NR1H2 | POLA1 2447/4885MEN1 2651/4885KMT2A 4576/4885 |
| US-20040142928-A1 | Heterocycle carboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, HDAC1 | POLA1 267/4885MEN1 2250/4885KMT2A 993/4885 |
| US-20020025960-A1 | Heterocycle carboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, HDAC1 | POLA1 267/4885MEN1 2250/4885KMT2A 993/4885 |
| US-20030207880-A1 | Heterocycle carboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, HDAC1 | POLA1 267/4885MEN1 2250/4885KMT2A 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.